A lthough still in its early days, CRISPR has already been called the most powerful scientific tool of the century. Using ...

A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes towards the controversial approach.

Both CRSP and NTLA are advancing in vivo gene editing therapies targeting large markets, with financial stability supporting ...

Caribou Biosciences shares rose after its CAR-T therapies showed high response rates and durable remissions in lymphoma and myeloma trials.

St. Jude researchers advance CASTs, enhancing precision and activity for next-generation genome-editing therapies.

In today's hyper-connected world, cyber threats are more sophisticated and frequent than ever - ransomware attacks, data breaches, social engineering scams, and advanced persistent threats targeting ...

NEW YORK, NY – Two prominent biotechnology companies, Vertex Pharmaceuticals and CRISPR Therapeutics, both led by Indian American CEOs, have been named to TIME’s 2025 list of the 100 Most Influential ...

Lozano is a rare disease mom, neuroscience Ph.D. candidate at UC Davis, and board member for the PURA Syndrome Foundation. In May, a historic moment in science and medicine was captured in a single ...

A red quarter of a circle with the words 'The Quarter Mark' beside it. A year-long series looking back on the most significant moments of the past 25 years, how they changed our world, and how they ...

In the latest close session, CRISPR Therapeutics AG (CRSP) was down 6.54% at $68.29. The stock trailed the S&P 500, which registered a daily gain of 1.56%. On the other hand, the Dow registered a gain ...